Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
sentiment,
Steve White first diagnosis (July 2016) was GBM. Surgery Aug.5, 2016. (95 % of the tumour removed)
Here is his story:
JOURNEY WITH BRAIN CANCER - STEVE WHITE BEATING CANCER WITH DENVAX
anders2211,
Steve White is a British patient who had treatment with APCEDEN in India.
He was diagnosed with glioblastoma multiforme wild-type in July 2016.
https://www.sthelensstar.co.uk/news/16907299.steve-white-thanks-supporters-after-news-that-brain-tumour-has-returned-despite-recent-surgery/
He has done a lot of volunteer work for the Brain Tumor Charity in the UK.
https://www.thebraintumourcharity.org/media-centre/news/policy-news/launch-less-survivable-cancers-taskforce-petition/
https://www.change.org/p/nhs-england-double-the-survival-rate-of-the-least-survivable-cancers-by-2029
Unfortunately, in the early hours of Thursday, October 3, 2018, Steve dies in Willowbrook Hospice.
https://www.sthelensstar.co.uk/news/17983494.funeral-inspirational-brain-tumour-fighter-steve-white-take-place-today/
Ryta Power
July 28, 2020
Today, Jim is a six-year survivor of a glioblastoma multi-forme brain tumor. His thinking is clearer, his short-term memory is improving, and he is able to participate and understand conversations with much more ease.
Due to Covid, Jim has had to to cease his physiotherapy and this impacts Jim positively because he does not like exercising. Unfortunately, it does not help his mobility. So we are hoping that we will reach a stage where we can commence Physio again. A big thank you to my family and to the friends who have kept in touch by phoning, texting or visiting.
Kristyn Power
3:17 a.m. · Jul.31, 2020
GBM dx on July 28, 2014... 6 year anniversary! Go Dad! Thanks #DCVax-L and #NWBO!! I can’t wait for more people to access this treatment!
Kristyn Power
6:24 a.m. · Aug.1, 2020
We got the results from Dad’s MRI today: “Opinion - Stable postoperative appearance. “ Things continue to be good
#NWBO #DCVax
GBM dx on July 28, 2014... 6 year anniversary! Go Dad!
— Kristyn Power, CFA (@KristynPower) July 31, 2020
Thanks #DCVax-L and #NWBO!!
I can’t wait for more people to access this treatment! pic.twitter.com/K57mBNgQFi
For the first time I find information about Robin Swart and his relationship with Advent Bioservices, although I follow the evolution of Sawston closely.
A week ago the Mill Lane Sawston website https://www.mill-lane-sawston.co.uk/ was : is coming soon
Today https://www.mill-lane-sawston.co.uk/ is : password-protected=login
anyone?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=154084831
hankmanhub,
I agree with biosectinvestor that they seem to be anticipating something binary.
The last couple of months I did a lot of DD and occasionally you get useful and “sensitive” information.
In the coming days, I expect additional information from one of the authorities involved in this trial.
It all seems to be connected.
69 authors!
Published: 29 May 2018
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
Linda M. Liau, Keyoumars Ashkan, David D. Tran, Jian L. Campian, John E. Trusheim, Charles S. Cobbs, Jason A. Heth, Michael Salacz, Sarah Taylor, Stacy D. D’Andre, Fabio M. Iwamoto, Edward J. Dropcho, Yaron A. Moshel, Kevin A. Walter, Clement P. Pillainayagam, Robert Aiken, Rekha Chaudhary, Samuel A. Goldlust, Daniela A. Bota, Paul Duic, Jai Grewal, Heinrich Elinzano, Steven A. Toms, Kevin O. Lillehei, Tom Mikkelsen, Tobias Walbert, Steven R. Abram, Andrew J. Brenner, Steven Brem, Matthew G. Ewend, Simon Khagi, Jana Portnow, Lyndon J. Kim, William G. Loudon, Reid C. Thompson, David E. Avigan, Karen L. Fink, Francois J. Geoffroy, Scott Lindhorst, Jose Lutzky, Andrew E. Sloan, Gabriele Schackert, Dietmar Krex, Hans-Jorg Meisel, Julian Wu, Raphael P. Davis, Christopher Duma, Arnold B. Etame, David Mathieu, Santosh Kesari, David Piccioni, Manfred Westphal, David S. Baskin, Pamela Z. New, Michel Lacroix, Sven-Axel May, Timothy J. Pluard, Victor Tse, Richard M. Green, John L. Villano, Michael Pearlman, Kevin Petrecca, Michael Schulder, Lynne P. Taylor, Anthony E. Maida, Robert M. Prins, Timothy F. Cloughesy, Paul Mulholland & Marnix L. Bosch -Show fewer authors
https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-018-1507-6#Ack1
Same name?
inveterate and Pharmboy46,
Job done, IMO.
Dr. Anthony E. Maida, Ph.D., was Senior Vice President - Clinical Research of Northwest Biotherapeutics. He originally joined the company in June 2011, as Chief Operating Officer. During 2013, Dr. Maida moved into the position of SVP, Clinical Research, reflecting his focus on the Company’s Phase III clinical trial program in the US, in which he had been playing a central role throughout 2012 and 2013 to date.
https://wallmine.com/otc/nwbo/officer/1643164/anthony-maida
This month Fanny Schömann started a new position as an Office Manager at Mannin Research GmbH.
Office Manager
Company Name:
Mannin Research GmbH Part-time
Dates Employed Jul 2020 – Present
Location Leipzig, Saxony, Germany
Head Of Operations
Company Name:
Northwest Biotherapeutics GmbH
Dates Employed Aug 2013 – Jul 2020
Employment Duration 7 yrs
I continue working for NWBio on a consultant basis.... working with the head of the company on day to day tasks, such as travel management, preparing meetings and calls, overlooking the contracts with clinics for the clinical trial. Also responsible for the book keeping and all tax relevant matters.
https://www.linkedin.com/in/fanny-sch%C3%B6mann-28557a11/
Anthony Maida, Ph.D started a new position as Chief Clinical Officer - Translational Medicine at Mateon/Oncotelic, Inc.(3 weeks ago)
Experience
Nuclear RNA Networks
Chief Scientific Officer - Translational Medicine
Company Name Nuclear RNA Networks Part-time
Dates Employed Jul 2020 – Present
Mateon/Oncotelic, Inc.
Chief Clinical Officer - Translational Medicine
Company Name Mateon/Oncotelic, Inc. Full-time
Dates Employed Jul 2020 – Present
Location Irvine, California, United States
Northwest Biotherapeutics, Inc.
Senior Vice President - Clinial Research
Company NameNorthwest Biotherapeutics, Inc.
Dates Employed Jun 2011 – Jul 2020
Employment Duration 9 yrs 2 mos
https://www.linkedin.com/in/anthonymaida/
A new employee.
Daniel Moore, MCITP, MCSA, ITIL V3
Director of Information Technology at Northwest Biotherapeutics.
Mike Scott
Chief Operating Officer at Advent Bioservices & Visiting Professor, Anglia Ruskin University
1d • 1 day ago
Advent Bioservices is seeking a Validation Lead. If you have the experience and want to join a vibrant team as we build our business, please get in touch.
As it’s #EyeWeek just wanted to thank @bootsopticians @westfieldlondon who back in October spotted pressure behind Laura’s eyes which on further investigation showed multiple brain tumours. A quick diagnosis can make all the difference @HeadSmartUK @BrainTumourOrg pic.twitter.com/kSRw86gISw
— shitscaredmum (@shitscaredmum) September 26, 2019
Ex, that was 2018! We are 2 years later. I think you're a little behind. Much has changed in those two years!
longfellow95,
I assume you found the information in this patent?
Johnnygogo,
I found this summary on a brain tumor patient forum. Hope that helps.
Jack2479,
Thank you for the information! I agree 100%.
You said that you visited the Sawston facility late last year and spoke to the team at Advent. Did they told you they want to receive GMP license for a closed production system used to manufacture their lead product?
I ask you because Advent Bioservices is working with Autolomous.
And a month ago Glycostem Therapeutics announced they have chosen Autolomous for the digitisation of the manufacturing and release of Glycostem's NK-cell therapies for clinical trials and beyond.
Thank you for the information. I know that he returned to the Netherlands last year. So, I suppose you can communicate with the professor in Dutch?